U. Shain Et Al. , "Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen," ANNALS OF ONCOLOGY , vol.20, no.12, pp.2019, 2009
Shain, U. Et Al. 2009. Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen. ANNALS OF ONCOLOGY , vol.20, no.12 , 2019.
Shain, U., Alkan, A., & Altundag, K., (2009). Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen. ANNALS OF ONCOLOGY , vol.20, no.12, 2019.
Shain, U., A. Alkan, And K. Altundag. "Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen," ANNALS OF ONCOLOGY , vol.20, no.12, 2019, 2009
Shain, U. Et Al. "Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen." ANNALS OF ONCOLOGY , vol.20, no.12, pp.2019, 2009
Shain, U. Alkan, A. And Altundag, K. (2009) . "Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen." ANNALS OF ONCOLOGY , vol.20, no.12, p.2019.
@article{article, author={U. Shain Et Al. }, title={Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen}, journal={ANNALS OF ONCOLOGY}, year=2009, pages={2019} }